ZB

Zura Bio Limited

ZURA·NASDAQ

$4.10

-5.9%
HealthcareBiotechnology

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$266.59M
EPS-1.0600
P/E Ratio-4.97
Earnings Date08/13/2026

zura

Other Non-Current Assets

Last Annual Value

1.51M

3-Year CAGR

-24%

5-Year CAGR

%

10-Year CAGR

%

ZB

Zura Bio Limited Competitors Analysis of Other Non-Current Assets

ZURA · NASDAQ
CompanyOther Non-Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
1.51M
N/AN/AN/A 
0.00
N/AN/AN/A
2.15M
10.7%17.2%N/A
573.88K
N/AN/AN/A
257.00K
-2.2%-15.4%10.3%
3.36M
-20.7%31.0%N/A
4.94M
624.3%N/AN/A
44.47M
250.3%237.1%N/A
3.83M
-12.3%1.3%N/A
0.00
N/AN/AN/A
312.00K
0.0%-28.8%2.0%
ZB

Zura Bio Limited Fair Value Envelope

ZURA · NASDAQ

Our analysis suggests that ZURA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.1, this represents a potential HIDDEN relative to our calculated worth for Zura Bio Limited.

Intrinsic Value
Current Price: $4.1